Compare VCTR & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VCTR | LQDA |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.5B |
| IPO Year | 2018 | 2020 |
| Metric | VCTR | LQDA |
|---|---|---|
| Price | $107.60 | $42.69 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $123.00 | $54.38 |
| AVG Volume (30 Days) | 470.8K | ★ 4.8M |
| Earning Date | 11-04-2026 | 11-06-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | ★ 3.01 | 1.26 |
| Revenue | ★ $413,412,000.00 | $158,320,000.00 |
| Revenue This Year | $26.25 | $357.27 |
| Revenue Next Year | $5.92 | $1.34 |
| P/E Ratio | $35.68 | ★ $31.31 |
| Revenue Growth | 0.92 | ★ 1031.18 |
| 52 Week Low | $57.03 | $22.05 |
| 52 Week High | $123.55 | $93.61 |
| Indicator | VCTR | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 44.15 | 47.91 |
| Support Level | $101.40 | $35.00 |
| Resistance Level | $117.85 | $46.67 |
| Average True Range (ATR) | 3.37 | 2.90 |
| MACD | -0.39 | 2.32 |
| Stochastic Oscillator | 33.21 | 99.56 |
Victory Capital Holdings Inc is a diversified investment management firm. The company provides specialized investment strategies to institutions, intermediaries, retirement platforms and individual investors. Its offerings include actively and passively managed mutual funds, rules-based and active exchange traded funds (ETFs), institutional separate accounts, variable insurance products (VIPs), alternative investments, private closed end funds, and a 529 Education Savings Plan. The company operates in one operating and reportable segment that provides investment management services and products to institutional, intermediary, retirement platforms and individual investors. The majority of the company's revenue consists of Investment management fees.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.